• Lobby the Congress on HR 1190 and S 1750. Lobby on issues pertaining to Medical Oncology and Community Cancer Centers in the United States.
• Lobby on issues pertaining to secondary insurance carriers policies (secondary to Medicare), as they pertain to Medical Oncology in Community Cancer Clinics. Part D issues, Coding for Services and Medications in the treatment of adults with cancer.
• Issues pertaining to Community Medical Oncology Practices. Medicare Reimbursement, Patient Access to Care, Coding for Services and Medications, ASP, Part B Drugs and Part D Plans, Medicare Advantage Plans. HR 1190 and S 1750
• Issues pertaining to Community Medical Oncology Practices and Pharmacy Departments in the Community Oncology Practice. ASP, Part B Drugs, Medicare Advantage, Part D, Formulary Issues, Access to Chemo Treatments, ESA Policy Rule Changes at CMS, Reimbursement and Coding for Services and Medications. HR 1190 and S 1750.

Duration: August 15, 2006 to present

May Have Ended?

General Issues: Health Issues, Insurance, Medicare/Medicaid, Pharmacy

Spending: about $0 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2006: Y Y The Administration, MEDPAC, CMS, OMB, CMS and OMB